Answers are grounded in this paper and cite their sources.
Taken together, we identified and characterized LCAT3 as a novel oncogenic lncRNA in the lung, and validated the LCAT3-FUBP1-MYC axis as a potential therapeutic target for LUAD.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: